• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Overview of Efalizumab Open-label Trials

Article

An open-label study was undertaken to evaluate the safety, tolerability, and efficacy of continuous efalizumab therapy in patients achieving PASI 50 or an OLS grade of Mild, Minimal, or Clear at 12 weeks of therapy.

Recent Videos
Related Content
Study Compares Dose Escalation with Biologics in Psoriasis

Study Compares Dose Escalation with Biologics in Psoriasis

Article
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Podcast
Publishing Excellence Runs More Than Skin Deep

Publishing Excellence Runs More Than Skin Deep

Article
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Podcast
Oral Zasocitinib Demonstrates Safety and Efficacy in Moderate to Severe Plaque Psoriasis

Oral Zasocitinib Demonstrates Safety and Efficacy in Moderate to Severe Plaque Psoriasis

Article
Derm In The News: September 1-7

Derm In The News: September 1-7

Article
© 2024 MJH Life Sciences

All rights reserved.